JP2018535647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535647A5 JP2018535647A5 JP2018513423A JP2018513423A JP2018535647A5 JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5 JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- ile
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 108091008874 T cell receptors Proteins 0.000 claims 19
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 1
- 108010037618 HLA-C*08 antigen Proteins 0.000 claims 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000713810 Rat sarcoma virus Species 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022188263A JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218688P | 2015-09-15 | 2015-09-15 | |
| US62/218,688 | 2015-09-15 | ||
| PCT/US2016/050875 WO2017048593A1 (en) | 2015-09-15 | 2016-09-09 | T cell receptors recognizing hla-cw8 restricted mutated kras |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188263A Division JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535647A JP2018535647A (ja) | 2018-12-06 |
| JP2018535647A5 true JP2018535647A5 (cg-RX-API-DMAC7.html) | 2019-10-17 |
| JP7185524B2 JP7185524B2 (ja) | 2022-12-07 |
Family
ID=56985686
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513423A Active JP7185524B2 (ja) | 2015-09-15 | 2016-09-09 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
| JP2022188263A Active JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188263A Active JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10556940B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3901169A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7185524B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102841067B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108350059B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2016323017B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3350213T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2879287T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257840B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018003062A (cg-RX-API-DMAC7.html) |
| SA (1) | SA518391109B1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201913868XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017048593A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| IL301894B2 (en) * | 2016-08-02 | 2025-02-01 | Us Health | Anti-KRAS-G20 T-cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP3602053B1 (en) * | 2017-03-31 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of isolating neoantigen-specific t cell receptor sequences |
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| BR112020005469A2 (pt) * | 2017-09-20 | 2020-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | receptores de células t restritivas a hla classe ii contra ras mutado |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| CR20200287A (es) * | 2017-12-04 | 2020-11-11 | Us Health | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado |
| JP7534962B2 (ja) | 2018-06-19 | 2024-08-15 | ビオンテック ユーエス インコーポレイテッド | ネオ抗原およびその使用 |
| CN112888707B (zh) | 2018-08-16 | 2025-04-25 | 百欧恩泰美国公司 | T细胞受体构建体及其用途 |
| CN120607607A (zh) * | 2019-01-22 | 2025-09-09 | 美国卫生和人力服务部 | 针对含有g12r突变的ras的hla第ii类限制性t细胞受体 |
| KR20210130189A (ko) | 2019-02-20 | 2021-10-29 | 프레드 헛친슨 켄서 리서치 센터 | Ras 신항원에 특이적인 결합 단백질 및 이의 용도 |
| US20220175899A1 (en) * | 2019-04-11 | 2022-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| US20210342750A1 (en) * | 2019-08-14 | 2021-11-04 | Nec Corporation | Information processing apparatus, information processing method, and storage medium |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| KR20220143875A (ko) * | 2020-02-14 | 2022-10-25 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체 |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| EP4182029B1 (en) * | 2020-07-16 | 2025-12-31 | The United States of America, as represented by the Secretary, Department of Health and Human Services | HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation |
| US20230365649A1 (en) * | 2020-10-02 | 2023-11-16 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| CA3209732A1 (en) | 2021-02-25 | 2022-09-01 | Drew Caldwell DENIGER | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920824B (zh) * | 2022-05-27 | 2023-12-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301017B2 (en) * | 2002-05-30 | 2007-11-27 | Kolesnick Richard N | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| EP3369812B1 (en) * | 2005-08-05 | 2020-10-07 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Generation of antigen specific t cells |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| CA3071740C (en) | 2010-09-20 | 2020-09-08 | Biontech Ag | Antigen-specific t cell receptors and t cell epitopes |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP3766896B1 (en) | 2011-09-15 | 2025-11-05 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| JP6863893B2 (ja) | 2014-11-26 | 2021-04-21 | アメリカ合衆国 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
-
2016
- 2016-09-09 EP EP21162567.8A patent/EP3901169A1/en active Pending
- 2016-09-09 CN CN201680058891.3A patent/CN108350059B/zh active Active
- 2016-09-09 ES ES16770408T patent/ES2879287T3/es active Active
- 2016-09-09 MX MX2018003062A patent/MX2018003062A/es unknown
- 2016-09-09 WO PCT/US2016/050875 patent/WO2017048593A1/en not_active Ceased
- 2016-09-09 SG SG10201913868XA patent/SG10201913868XA/en unknown
- 2016-09-09 KR KR1020187010326A patent/KR102841067B1/ko active Active
- 2016-09-09 KR KR1020257025325A patent/KR20250117744A/ko active Pending
- 2016-09-09 EP EP16770408.9A patent/EP3350213B1/en active Active
- 2016-09-09 DK DK16770408.9T patent/DK3350213T3/da active
- 2016-09-09 CN CN202111083392.9A patent/CN115073583A/zh active Pending
- 2016-09-09 IL IL257840A patent/IL257840B2/en unknown
- 2016-09-09 JP JP2018513423A patent/JP7185524B2/ja active Active
- 2016-09-09 US US15/758,954 patent/US10556940B2/en active Active
- 2016-09-09 AU AU2016323017A patent/AU2016323017B2/en active Active
-
2018
- 2018-03-13 SA SA518391109A patent/SA518391109B1/ar unknown
-
2020
- 2020-01-10 US US16/739,310 patent/US11667692B2/en active Active
-
2021
- 2021-02-10 AU AU2021200833A patent/AU2021200833B2/en active Active
-
2022
- 2022-07-26 AU AU2022209229A patent/AU2022209229B2/en active Active
- 2022-11-25 JP JP2022188263A patent/JP7461445B2/ja active Active
-
2023
- 2023-05-01 US US18/310,141 patent/US20230406904A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535647A5 (cg-RX-API-DMAC7.html) | ||
| IL273254B1 (en) | Hla class ii–restricted t cell receptors against mutated ras | |
| JP2017536825A5 (cg-RX-API-DMAC7.html) | ||
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2015535816A5 (cg-RX-API-DMAC7.html) | ||
| JP2015525208A5 (cg-RX-API-DMAC7.html) | ||
| ES2984937T3 (es) | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1 | |
| JP2020511936A5 (cg-RX-API-DMAC7.html) | ||
| FI3294333T4 (fi) | Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit | |
| RS55822B1 (sr) | Terapijski peptidi | |
| EP4480967A1 (en) | Development and use of novel immunomodulator | |
| JP2016503295A5 (cg-RX-API-DMAC7.html) | ||
| JP2017524372A5 (cg-RX-API-DMAC7.html) | ||
| RU2018128215A (ru) | Антитела против mica | |
| KR20180016321A (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
| JP2013502913A5 (cg-RX-API-DMAC7.html) | ||
| JP2019536426A (ja) | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド | |
| RU2016124670A (ru) | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения | |
| CN113527473A (zh) | 一种全人源单克隆抗体及其应用 | |
| CN110194799A (zh) | 结合犬pd-1的抗犬pd-1抗体 | |
| JP2017536821A5 (cg-RX-API-DMAC7.html) | ||
| CN112094348A (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| Zuo et al. | A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding | |
| CA2967778A1 (en) | Anti-thyroglobulin t cell receptors | |
| CN111344305B (zh) | 抗pd-l1的抗体及其用途 |